Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers

BJU International

Volumn 110, Issue 6, 2012, Pages 840-845

  Dhani, Neesha C ^a   Emmenegger, Urban ^b   Adams, Laurie ^a   Jongstra, Jan ^c   Tannock, Ian F ^a   Sridhar, Srikala S ^a   Knox, Jennifer J ^a   Day, John R ^d   Groskopf, Jack ^d   Joshua, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d Gen Probe Incorporated   (United States)

Author keywords

cytarabine; prostate cancer; SPINK1; TMPRSS2 ERG

Indexed keywords

BIOLOGICAL MARKER; CYTARABINE; DOCETAXEL; INDOMETACIN; MESSENGER RNA; MITOXANTRONE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR KAZAL TYPE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CANCER PATIENT; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; EXON; FATIGUE; FEBRILE NEUTROPENIA; GENE ACTIVITY; GENE FUNCTION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RNA ANALYSIS; SIDE EFFECT; SKIN BRUISING; SPINK1 GENE; THROMBOCYTOPENIA; TMPRSS2 ERG GENE; TREATMENT OUTCOME; WOUND INFECTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARRIER PROTEINS; CASTRATION; CYTARABINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TAXOIDS; TRANS-ACTIVATORS;

EID: 84865511635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10922.x     Document Type: Article

References (30)

1. Society AC,. Cancer Facts and Figures 2011. Atlanta: American Cancer Society, 2011
2. de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
3. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
4. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
5. Petrovics G, Liu A, Shaheduzzaman S, et al,. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-52
6. Tomlins SA, Laxman B, Varambally S, et al,. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-88
7. Tomlins SA, Rhodes DR, Perner S, et al,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8
8. Mehra R, Tomlins SA, Shen R, et al,. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-44
9. Ateeq B, Tomlins SA, Laxman B, et al,. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17
10. Stegmaier K, Wong JS, Ross KN, et al,. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007; 4: e122
11. Gandhok N, Sartor O,. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen. Urology 2004; 64: 807-9
12. Scher HI, Halabi S, Tannock I, et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
13. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16
14. Nelius T, Filleur S,. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 2009; 69: 1802-7
15. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al,. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006; 8: 465-9
16. Yoshimoto M, Joshua AM, Cuhna IW, et al,. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-60
17. Yoshimoto M, Ludkovski O, Bayani J, Graham C, Zielenska M, Squire JA,. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 2007; 46: 861-3
18. Leinonen KA, Leinonen KA, Tolonen TT, et al,. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-51
19. Groskopf J, Aubin SM, Deras IL, et al,. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95
20. Jost M, Day JR, Slaughter R, et al,. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 2010; 9: 174
21. Wang J, Cai Y, Ren C, Ittmann M,. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347-51
22. DuBois S, Krailo MD, Lessnick SL, et al,. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52: 324-7
23. Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Uren A,. YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion. PLoS ONE 2010; 6: e19343
24. Gopalan A, Leversha MA, Satagopan JM, et al,. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-6
25. Danila DC, Fleisher M, Scher HI,. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-12
26. Danila DC, Anand A, Sung CC, et al,. TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate. Eur Urol 2011; 60: 897-904
27. Stott SL, Hsu CH, Tsukrov DI, et al,. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010; 107: 18392-7
28. Danila DC, Danila DC, Heller G, Gignac GA, et al,. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-8
29. Stott SL, Lee RJ, Nagrath S, et al,. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra23
30. Helo P, Cronin AM, Danila DC, et al,. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55: 765-73